All In Biotech

Drug Trial Radar · NCT05496738

A Preliminary Study to Evaluate PF-07264660 in Healthy Participants

A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE AND MULTIPLE INTRAVENOUS AND SUBCUTANEOUS DOSES OF PF-07264660 IN HEALTHY PARTICIPANTS

Last checked: Nov 20, 2026Latest source record: Jun 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

59

Actual

Start

Aug 16, 2022

Primary completion

May 6, 2024

Study completion May 6, 2024

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Aug 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to learn about the safety and effects of study medicine PF-07264660 compared to a placebo. This is the first study of PF-07264660 in humans. All participants in this study will received PF-07264660 or a placebo and it will be assigned by chance. People may be able to participate if they are healthy. The study medicine may be given by shots under the skin or through a vein depending on which group you are assigned to. If you are assigned into Part A, you will receive the study medicine once, stay overnight at the research unit from 3 to 5 overnight stays and you will need to visit the clinic about 11 follow-up visits. Participants will be in this study for up to about 541 days. If you are assigned into Part B, you will receive the study medicine three times, stay overnight at the clinic from 3 to 5 overnight stays and you will need to visit the research unit about 12 follow-up visits. Participants willbe in this study for up to about 561 days.

Conditions

  • Healthy

Interventions

  • PF-07264660 intravenous single ascending doseDrug

    PF-07264660 will be administered intravenously in single ascending doses

  • PF-07264660 subcutaneous multiple ascending doseDrug

    PF-07264660 will be administered subcutaneously in multiple ascending doses

  • Intravenous placeboOther

    Placebo will be administered intravenously in single ascending doses

  • subcutaneous placeboOther

    Placebo will be administered subcutaneously in multiple ascending doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment emergent treatment related adverse events (AE's)Time frame: Baseline up to approximately 1.5 years
  2. Number of participants with treatment emergent treatment-related serious adverse events (SAE's)Time frame: Baseline up to approximately 1.5 years
  3. Number of participants with change from baseline in blood pressureTime frame: Baseline up to approximately 1.5 years
  4. Number of participants with change from baseline in pulse rateTime frame: Baseline up to approximately 1.5 years
  5. Number of participants with change from baseline in temperatureTime frame: Baseline up to approximately 1.5 years
  6. Number of participants with change from baseline in clinical laboratory valuesTime frame: Baseline up to approximately 1.5 years
  7. Number of participants with change from baseline in heart rateTime frame: Baseline up to approximately 1.5 years
  8. Number of participants with change from baseline in QT intervalTime frame: Baseline up to approximately 1.5 years
  9. Number of participants with change from baseline in corrected QT intervalTime frame: Baseline up to approximately 1.5 years
  10. Number of participants with change from baseline in PR intervalTime frame: Baseline up to approximately 1.5 years
  11. Number of participants with change from baseline in QRS intervalTime frame: Baseline up to approximately 1.5 years

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Collaborative Neuroscience Research, LLC

    Garden Grove, California

  • Collaborative Neuroscience Research, LLC

    Long Beach, California

  • Collaborative Neuroscience Research, LLC

    Los Alamitos, California

  • Prism Research LLC dba Nucleus Network

    Saint Paul, Minnesota

  • Clinical Trials of Texas, LLC

    San Antonio, Texas

  • Spaulding Clinical Research

    West Bend, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.